McN3716 is a carnitine palmitoyltransferase I ( CPT-1 ) inhibitor. Form:Solid IC50& Target:Carnitine palmitoyltransferase I (CPT-1) In Vivo:Inhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF 1α , a byproduct of PGI 2 (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle [1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.